Sun Chen-Hui, Zheng Wei, Yang Xin-Hu, Cai Dong-Bin, Ng Chee H, Ungvari Gabor S, Li Hai-Yan, Wu Yu-Jie, Ning Yu-Ping, Xiang Yu-Tao
Qingdao Mental Health Center, Shandong, China.
The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.
Shanghai Arch Psychiatry. 2017 Jun 25;29(3):129-136. doi: 10.11919/j.issn.1002-0829.217046.
Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly, TD could cause considerable personal suffering and social and physical disabilities.
This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the therapeutic effect and tolerability of melatonin for TD in schizophrenia.
A computerized and systematical search of both Chinese (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED) and English (PubMed, PsycINFO, Embase, Cochrane Library databases) databases, from their inception until June 8, 2017, was conducted by two independent authors. The severity of TD symptoms were the primary outcome measure and analyzed using a random effects model by the Review Manager (RevMan) Version 5.3. Quality evaluation of included RCTs was conducted using the Cochrane risk of bias and Jadad scale. The GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system recommendation grading method was used to assess the overall quality level of meta-analytic outcomes.
Four RCTs (n=130) were identified and analyzed. Three RCTs used double blind and 1 RCT used masked assessors using the Cochrane risk of bias, and 3 RCTs were rated as high quality based on Jadad scale. Compared with the control group, adjunctive melatonin was superior in reducing the severity of TD as measured by the Abnormal Involuntary Movement Scale (AIMS) (4 RCTs, n=130, weighted mean difference (WMD): -1.52 (95% confidence intervals (CI): -3.24, 0.20), =0.08; =0%) although the improvement did not reach a significant level. The overall evidence quality of the improvement of TD symptoms, according to GRADE approach, was rated as "Low". The data on the ADRs and cognitive effect were limited.
This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. Future higher quality and larger RCTs are warranted to confirm the findings.
迟发性运动障碍(TD)的特征为异常的不自主运动。重要的是,TD可导致相当大的个人痛苦以及社交和身体残疾。
本基于随机对照试验(RCT)的荟萃分析系统评估了褪黑素治疗精神分裂症患者TD的疗效和耐受性。
由两名独立作者对中文数据库(万方数据、中国知网、中国生物医学文献数据库)和英文数据库(PubMed、PsycINFO、Embase、Cochrane图书馆数据库)进行计算机系统检索,检索时间范围从建库至2017年6月8日。以TD症状严重程度作为主要结局指标,采用RevMan 5.3软件的随机效应模型进行分析。采用Cochrane偏倚风险评估和Jadad量表对纳入的RCT进行质量评价。采用推荐分级的评估、制定与评价(GRADE)系统推荐分级方法评估荟萃分析结果的整体质量水平。
共纳入并分析了4项RCT(n = 130)。根据Cochrane偏倚风险评估,3项RCT采用双盲法,1项RCT采用盲法评估,根据Jadad量表,3项RCT被评为高质量。与对照组相比,添加褪黑素在降低异常不自主运动量表(AIMS)所测得的TD严重程度方面更具优势(4项RCT,n = 130,加权均数差(WMD):-1.52(95%置信区间(CI):-3.24,0.20),P = 0.08;I² = 0%),尽管改善未达到显著水平。根据GRADE方法,TD症状改善的总体证据质量被评为“低”。关于不良反应和认知效应的数据有限。
本荟萃分析表明,褪黑素具有改善精神分裂症患者TD症状的潜力。未来需要更高质量、更大规模的RCT来证实这些发现。